T1	Participants 63 82	chronic hepatitis C
T2	Participants 119 152	patients with chronic hepatitis C
T3	Participants 484 589	1,046 patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial
T4	Participants 591 703	All patients had failed prior treatment with IFN or peginterferon +/- RBV and had Ishak fibrosis scores > or = 3
T5	Participants 705 781	Four groups of patients with increasingly severe liver disease were compared
T6	Participants 1669 1711	patients with advanced chronic hepatitis C
T7	Participants 1778 1806	"difficult-to-cure" patients
